February 16, 2024
2 mins read

India rejects EU’s data exclusivity demand  

Commerce Secretary Sunil Barthwal said that there is no free trade agreement (FTA) in which India will go against the generic drug industry. ..reports Asian Lite News

India will continue to protect the interests of its generic drug firms and has rejected European Free Trade Association (EFTA) nations’ demand to keep “data exclusivity” as a part of the intellectual property (IP) chapter under a proposed bilateral trade deal, a top government official said on Thursday.

Commerce Secretary Sunil Barthwal said that there is no free trade agreement (FTA) in which India will go against the generic drug industry. EFTA comprises Iceland, Switzerland, Norway and Liechtenstein.

“They want there should be data exclusivity, but we rejected their demand. We are with our generic industry. There is no fear for the Indian generic industry (from this agreement). In fact, it is our very important objective to see that the generic drug industry flourishes,” Barthway told reporters.

For over a decade, India has been against the inclusion of data exclusivity provisions in FTAs to protect the interest of the domestic generic drug industry. Through data exclusivity, technical data generated by innovator companies get protection, which stops their competitors from getting cheaper versions of the medicine for a certain time period or till the innovator companies have ‘exclusivity rights’.

Even in the past, India’s discussions on IPR have been a contentious issue in FTA negotiations with countries such as Japan, the United Kingdom (UK) and trade blocs such as the European Union (EU).

According to international medical humanitarian organisation Doctors Without Borders/ Médecins Sans Frontières (MSF), Public Eye, and Delhi Network of Positive People, the draft leaked chapter on IP has provisions on data exclusivity, which can hamper the production of cheap, lifesaving generic medicines from India.

“This would result in generic manufacturers either needing to wait out the exclusivity period or repeat expensive clinical trials. In cases where a new medicine is patented, data exclusivity could block compulsory licences that may be granted to generic manufacturers to produce medicines at lower prices,” said a statement from MSF on Wednesday.

ALSO READ: US, UK carry out fresh strikes in Yemen

Previous Story

Indian, Chinese firms helping Russia may face EU curbs

Next Story

‘India Unfazed by England’s Bazball Talk’

Latest from -Top News

India wins unopposed seat on UNHRC

India last served on the HRC in 2024, completing a second consecutive term….reports Asian Lite News India has been elected unopposed to the UN Human Rights Council (HRC) for the seventh time,

Relief Rolls In, Restrictions Remain in Gaza

Israeli official noted an Israeli statement saying it would limit the number of aid truckloads entering the Gaza Strip to 300 daily…reports Asian Lite News Relief operations in Gaza have intensified since

Madagascar Under Military Rule

Colonel Michael Randrianirina announced on Tuesday that a military council of the army, gendarmerie, and police has taken control of Madagascar….reports Asian Lite News Colonel Michael Randrianirina, a Malagasy military officer, announced

Pakistan Faces Rising Uprisings

Officials warn that Pakistan cannot continue suppressing such protests by force indefinitely. A breaking point, they say, is inevitable — when the growing discontent converges into a major challenge for the establishment
Go toTop

Don't Miss

Indian investors eye Suez Canal region as PM visits Cairo

Prime Minister Narendra Modi’s maiden visit to Cairo is happening

Pakistani Handles Banned Again in India

The move comes in continuation of India’s escalating digital and